PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
3.56%
Cash & equivalents changing by 3.56% while Biotechnology maintains stable levels. Benjamin Graham would examine if this divergence is justified.
-100.00%
Short-term investments yoy growth below half the Biotechnology median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
3.51%
Below half the Biotechnology median of -0.39% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.27%
Below half the Biotechnology median of -1.29%. Jim Chanos would question if the company faces working capital strain.
11.32%
PP&E growth ≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-18.41%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Below half the Biotechnology median of -0.38%. Jim Chanos might see potential stagnation or distress vs. peers.
65.90%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
126.86%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
114.06%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
114.06%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
5.13%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-6.19%
≥ 1.5x Biotechnology median of -2.03%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-12.13%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
-4.02%
≥ 1.5x Biotechnology median of -0.97%. Joel Greenblatt sees stronger equity growth vs. peers.
6.14%
Below half Biotechnology median of -0.38%. Jim Chanos suspects a major slowdown or distress.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-2.49%
Above 1.5x Biotechnology median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.